Remarkable pathological response to neoadjuvant tepotinib in lung adenocarcinoma with MET exon 14 skipping mutation: A case report

被引：2

作者：

Li, Rongzhen ^{[1
,2
]}

Liu, Xiaoyan ^{[1
]}

Xu, Yan ^{[1
]}

Zhao, Jing ^{[1
]}

Zhong, Wei ^{[1
]}

Gao, Xiaoxing ^{[1
]}

Chen, Minjiang ^{[1
]}

Wang, Mengzhao ^{[1
]}

机构：

[1] Chinese Acad Med Sci & Peking Union Med Coll, Peking Union Med Coll Hosp, Dept Resp & Crit Care Med, Beijing 100730, Peoples R China

[2] Chinese Acad Med Sci & Peking Union Med Coll, Beijing, Peoples R China

来源：

THORACIC CANCER | 2024年 / 15卷 / 32期

关键词：

MET exon 14 skipping mutation; neoadjuvant; non-small cell lung cancer; tepotinib;

D O I：

10.1111/1759-7714.15459

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Mesenchymal-epithelial transition (MET) exon 14 (METex14) skipping mutation is a rare (3%-4%) driver mutation in non-small cell lung cancer (NSCLC). Tepotinib, a selective MET inhibitor, has shown promise in treating METex14 skipping-mutated NSCLC. However, its feasibility for perioperative application remains unclear. This report describes a 60-year-old man with stage IIIA (cT2N2M0) lung adenocarcinoma harboring a METex14 skipping mutation. After initial treatment with savolitinib was discontinued due to grade 4 transaminitis, the patient was switched to tepotinib, resulting in significant tumor regression. Six months later, further shrinkage was observed, and surgery revealed remarkable pathological response with no residual tumor in lymph nodes (ypT2N0M0, IB). Postoperative tepotinib continued, with no relapse at 6-month follow-up. This case highlights the potential of tepotinib as neoadjuvant therapy for resectable METex14 skipping-mutated NSCLC, warranting further clinical trials.

引用

页码：2339 / 2343

页数：5

共 19 条

[1] Neoadjuvant Osimertinib for the Treatment of Stage I-IIIA Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: A Phase II Multicenter Study [J].

Blakely, Collin M. ;

Urisman, Anatoly ;

Gubens, Matthew A. ;

Mulvey, Claire K. ;

Allen, Greg M. ;

Shiboski, Stephen C. ;

Rotow, Julia K. ;

Chakrabarti, Turja ;

Kerr, D. Lucas ;

Aredo, Jacqueline V. ;

Bacaltos, Bianca ;

Gee, Megan ;

Tan, Lisa ;

Jones, Kirk D. ;

Devine, W. Patrick ;

Doebele, Robert C. ;

Aisner, Dara L. ;

Patil, Tejas ;

Schenk, Erin L. ;

Bivona, Trever G. ;

Riess, Jonathan W. ;

Coleman, Melissa ;

Kratz, Johannes R. ;

Jablons, David M. .

JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (26) :3105-3114

[2]

Carbone D, 2021, J THORAC ONCOL, V16, pS115, DOI 10.1016/j.jtho.2021.01.294

[3] The safety and feasibility of preoperative induction therapy of Savolitinib in non-small cell lung cancer patients with MET exon 14 skipping mutation [J].

Deng, Han-Yu ;

Qiu, Xiao-Ming ;

Zhu, Da-Xing ;

Tang, Xiao-Jun ;

Zhou, Qinghua .

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (08) :4623-4628

[4] Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration [J].

Drilon, Alexander ;

Clark, Jeffrey W. ;

Weiss, Jared ;

Ou, Sai-Hong Ignatius ;

Camidge, D. Ross ;

Solomon, Benjamin J. ;

Otterson, Gregory A. ;

Villaruz, Liza C. ;

Riely, Gregory J. ;

Heist, Rebecca S. ;

Awad, Mark M. ;

Shapiro, Geoffrey I. ;

Satouchi, Miyako ;

Hida, Toyoaki ;

Hayashi, Hidetoshi ;

Murphy, Danielle A. ;

Wang, Sherry C. ;

Li, Sherry ;

Usari, Tiziana ;

Wilner, Keith D. ;

Paik, Paul K. .

NATURE MEDICINE, 2020, 26 (01) :47-+

[5] Neoadjuvant Savolitinib targeted therapy stage IIIA-N2 primary lung adenocarcinoma harboring MET Exon 14 skipping mutation: A case report [J].

Fu, Meng ;

Feng, Chun-Mei ;

Xia, Da-Qing ;

Ji, Zi-Mei ;

Xia, Huai-Ling ;

Hu, Na-Na ;

Leng, Zai-Jun ;

Xie, Wang ;

Fang, Yuan ;

Cao, Le-Jie ;

Zhang, Jun-Qiang .

FRONTIERS IN ONCOLOGY, 2022, 12

[6]

Furqan M, 2023, J CLIN ONCOL, V41

[7] Perioperative Durvalumab for Resectable Non-Small-Cell Lung Cancer [J].

Heymach, John V. ;

Harpole, David ;

Mitsudomi, Tetsuya ;

Taube, Janis M. ;

Galffy, Gabriella ;

Hochmair, Maximilian ;

Winder, Thomas ;

Zukov, Ruslan ;

Garbaos, Gabriel ;

Gao, Shugeng ;

Kuroda, Hiroaki ;

Ostoros, Gyula ;

Tran, Tho V. ;

You, Jian ;

Lee, Kang-Yun ;

Antonuzzo, Lorenzo ;

Papai-Szekely, Zsolt ;

Akamatsu, Hiroaki ;

Biswas, Bivas ;

Spira, Alexander ;

Crawford, Jeffrey ;

Le, Ha T. ;

Aperghis, Mike ;

Doherty, Gary J. ;

Mann, Helen ;

Fouad, Tamer M. ;

Reck, Martin .

NEW ENGLAND JOURNAL OF MEDICINE, 2023, 389 (18) :1672-1684

[8] Savolitinib: First Approval [J].

Markham, Anthony .

DRUGS, 2021, 81 (14) :1665-1670

[9] Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry [J].

Mazieres, J. ;

Drilon, A. ;

Lusque, A. ;

Mhanna, L. ;

Cortot, A. B. ;

Mezquita, L. ;

Thai, A. A. ;

Mascaux, C. ;

Couraud, S. ;

Veillon, R. ;

Van Den Heuvel, M. ;

Neal, J. ;

Peled, N. ;

Fruh, M. ;

Ng, T. L. ;

Gounant, V ;

Popat, S. ;

Diebold, J. ;

Sabari, J. ;

Zhu, V. W. ;

Rothschild, S. I. ;

Bironzo, P. ;

Martinez-Marti, A. ;

Curioni-Fontecedro, A. ;

Rosell, R. ;

Lattuca-Truc, M. ;

Wiesweg, M. ;

Besse, B. ;

Solomon, B. ;

Barlesi, F. ;

Schouten, R. D. ;

Wakelee, H. ;

Camidge, D. R. ;

Zalcman, G. ;

Novello, S. ;

Ou, S. I. ;

Milia, J. ;

Gautschi, O. .

ANNALS OF ONCOLOGY, 2019, 30 (08) :1321-1328

[10] MET Exon 14 Skipping in NSCLC: A Systematic Literature Review of Epidemiology, Clinical Characteristics, and Outcomes [J].

Mazieres, Julien ;

Vioix, Helene ;

Pfeiffer, Boris M. ;

Campden, Rhiannon I. ;

Chen, Zhiyuan ;

Heeg, Bart ;

Cortot, Alexis B. .

CLINICAL LUNG CANCER, 2023, 24 (06) :483-497

← 1 2 →